Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Autoimmune Disorders

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 64 articles:
HTML format



Single Articles


    February 2024
  1. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    PubMed     Abstract available


  2. VAN DER HELM-VAN MIL AHM
    Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
    Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
    PubMed    


    January 2024
  3. WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al
    Complement in human disease: approved and up-and-coming therapeutics.
    Lancet. 2024;403:392-405.
    PubMed     Abstract available


    November 2023
  4. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
    Multiple sclerosis.
    Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
    PubMed     Abstract available


  5. REICH HN, Barbour SJ
    PROTECTing the kidneys in IgA nephropathy.
    Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418.
    PubMed    


  6. ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al
    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302.
    PubMed     Abstract available


  7. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available


    October 2023
  8. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    PubMed     Abstract available


  9. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    PubMed     Abstract available


  10. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    PubMed    


    September 2023
  11. BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al
    Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460.
    PubMed     Abstract available


  12. MAHAMAD S, Arnold DM
    Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
    Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836.
    PubMed    


  13. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126.
    PubMed     Abstract available


    August 2023
  14. LAFAYETTE R, Kristensen J, Stone A, Floege J, et al
    Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lancet. 2023 Aug 14:S0140-6736(23)01554-4. doi: 10.1016/S0140-6736(23)01554.
    PubMed     Abstract available


  15. HARALDSSON B
    Phase 3 trial results bring hope for patients with IgA nephropathy.
    Lancet. 2023 Aug 14:S0140-6736(23)01633-1. doi: 10.1016/S0140-6736(23)01633.
    PubMed    


  16. RAMANAN AV, Quartier P, Okamoto N, Foeldvari I, et al
    Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Lancet. 2023;402:555-570.
    PubMed     Abstract available


    July 2023
  17. RIFE EC, Cron RQ
    Janus kinase inhibition in juvenile idiopathic arthritis.
    Lancet. 2023 Jul 6:S0140-6736(23)01134-0. doi: 10.1016/S0140-6736(23)01134.
    PubMed    


    June 2023

  18. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301.
    PubMed     Abstract available


  19. DAVIES MJ, Ahmad E, Lim S, Lamptey R, et al
    Cancer is becoming the leading cause of death in diabetes - Authors' reply.
    Lancet. 2023;401:1849-1850.
    PubMed    


    May 2023
  20. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    PubMed     Abstract available


  21. WEN X, Li B
    A population-based study on autoimmune disease.
    Lancet. 2023 May 5:S0140-6736(23)00621-9. doi: 10.1016/S0140-6736(23)00621.
    PubMed    


    April 2023
  22. QUATTRIN T, Mastrandrea LD, Walker LSK
    Type 1 diabetes.
    Lancet. 2023 Apr 5:S0140-6736(23)00223-4. doi: 10.1016/S0140-6736(23)00223.
    PubMed     Abstract available


    March 2023
  23. LUNDBERG S, Bergen K
    We can go further in non-immunosuppressive treatment of IgA nephropathy.
    Lancet. 2023 Mar 31:S0140-6736(23)00630-X. doi: 10.1016/S0140-6736(23)00630.
    PubMed    


  24. HEERSPINK HJL, Radhakrishnan J, Alpers CE, Barratt J, et al
    Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
    Lancet. 2023 Mar 31:S0140-6736(23)00569-X. doi: 10.1016/S0140-6736(23)00569.
    PubMed     Abstract available


  25. DURCAN L, Murphy G
    SLE-BRAVE I and II.
    Lancet. 2023;401:972-973.
    PubMed    


  26. GREGG EW, Buckley J, Ali MK, Davies J, et al
    Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.
    Lancet. 2023 Mar 14:S0140-6736(23)00001-6. doi: 10.1016/S0140-6736(23)00001.
    PubMed     Abstract available


    February 2023
  27. PETRI M, Bruce IN, Dorner T, Tanaka Y, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Lancet. 2023 Feb 24:S0140-6736(22)02546-6. doi: 10.1016/S0140-6736(22)02546.
    PubMed     Abstract available


  28. MORAND EF, Vital EM, Petri M, van Vollenhoven R, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Lancet. 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
    PubMed     Abstract available


    January 2023
  29. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    PubMed     Abstract available


  30. GUGER M, Ransmayr G, Sonnberger M, Hametner S, et al
    Tumefactive multiple sclerosis presents with painless progressive hemiparesis and aphasia.
    Lancet. 2023;401:226.
    PubMed    


  31. CONRAD N, McMurray JJV
    Cardiovascular risk in systemic autoimmune diseases - Authors' reply.
    Lancet. 2023;401:22.
    PubMed    


  32. FUNADA S, Luo Y, Nishioka N, Yoshioka T, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21.
    PubMed    


  33. CAFARO G, Perricone C, Gerli R, Bartoloni E, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21-22.
    PubMed    


    December 2022
  34. HEBBINK JA, Nobels-Janssen E, Verhagen I, Kusters B, et al
    Subacute parkinsonism due to systemic lupus erythematosus and catastrophic antiphospholipid syndrome.
    Lancet. 2022;400:1966.
    PubMed    


    October 2022
  35. WIECH T, Reinhard L, Wulf S, Giuffrida AE, et al
    Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)02039.
    PubMed    


    August 2022
  36. RIDKER PM
    Autoimmune diseases and atherothrombotic risk.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01602.
    PubMed    


  37. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    PubMed     Abstract available


    May 2022
  38. RUPERTO N, Brunner HI, Posner HB, Lazariciu I, et al
    Tofacitinib for juvenile idiopathic arthritis - Authors' reply.
    Lancet. 2022;399:1866.
    PubMed    


  39. MURRAY GM, Renton WD
    Tofacitinib for juvenile idiopathic arthritis.
    Lancet. 2022;399:1865-1866.
    PubMed    


    April 2022
  40. SETHI S, De Vriese AS, Fervenza FC
    Acute glomerulonephritis.
    Lancet. 2022;399:1646-1663.
    PubMed     Abstract available


  41. PRASAD A
    Angela Migowa: advocating for children with rheumatic diseases.
    Lancet. 2022;399:1294.
    PubMed    


    March 2022
  42. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
    Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
    Lancet. 2022;399:1154.
    PubMed    


    January 2022
  43. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    PubMed    


    November 2021
  44. CLARKE SLN, Ramanan AV
    Tofacitinib in juvenile idiopathic arthritis.
    Lancet. 2021;398:1943-1945.
    PubMed    


  45. RUPERTO N, Brunner HI, Synoverska O, Ting TV, et al
    Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
    Lancet. 2021;398:1984-1996.
    PubMed     Abstract available


  46. LODGE FM, Moody WE, Tosounidou S, Chue CD, et al
    Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding.
    Lancet. 2021;398:1913.
    PubMed    


  47. BHUTTA ZA, Salam RA, Gomber A, Lewis-Watts L, et al
    A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.
    Lancet. 2021;398:1837-1850.
    PubMed     Abstract available


  48. HELLER SR, Durrant A, Tandon N
    Insulin, the patient, and the health professional.
    Lancet. 2021;398:1785-1786.
    PubMed    


  49. THE LANCET
    100 years of insulin: a technical success but an access failure.
    Lancet. 2021;398:1777.
    PubMed    


  50. DEVI S
    Cold comfort: getting insulin to those who need it.
    Lancet. 2021;398:1791.
    PubMed    


    October 2021
  51. CHEN LYC, Slack GW, Carruthers MN
    IgG4-related disease and Rosai-Dorfman-Destombes disease.
    Lancet. 2021;398:1213-1214.
    PubMed    


  52. EMILE JF, Vaglio A, Cohen-Aubart F, Haroche J, et al
    IgG4-related disease and Rosai-Dorfman-Destombes disease - Authors' reply.
    Lancet. 2021;398:1214-1215.
    PubMed    


    August 2021
  53. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    PubMed     Abstract available


    July 2021
  54. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    PubMed    


  55. HAWKINS P, Chawke L, Cormican L, Wikenheiser-Brokamp KA, et al
    Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.
    Lancet. 2021;398:e7.
    PubMed    


    June 2021
  56. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    PubMed     Abstract available


  57. NORGAARD K, Schmidt S
    Is reimbursement for alerts and real-time continuous glucose monitoring needed?
    Lancet. 2021;397:2230-2232.
    PubMed    


  58. TSAGKAS C, Schafer S, Baumgartner A, Muller J, et al
    Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.
    Lancet. 2021;397:2194.
    PubMed    


  59. VISSER MM, Charleer S, Fieuws S, De Block C, et al
    Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)00789.
    PubMed     Abstract available


    May 2021
  60. ROVIN BH, Teng YKO, Ginzler EM, Arriens C, et al
    Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00578.
    PubMed     Abstract available


  61. MOK CC
    A new old treatment for lupus nephritis.
    Lancet. 2021 May 7. pii: S0140-6736(21)00663.
    PubMed    


    April 2021
  62. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    PubMed    


  63. MIZELLE RM JR
    Diabetes, race, and amputations.
    Lancet. 2021;397:1256-1257.
    PubMed    


    October 2020
  64. HABIB SM, Vermeer MH
    A baby with red plaques on the face and a first-degree heart block: neonatal lupus.
    Lancet. 2020;396:1432.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.